HUP0000489A2 - 5-HT-Receptor affinitású szulfonamidszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
5-HT-Receptor affinitású szulfonamidszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0000489A2 HUP0000489A2 HU0000489A HUP0000489A HUP0000489A2 HU P0000489 A2 HUP0000489 A2 HU P0000489A2 HU 0000489 A HU0000489 A HU 0000489A HU P0000489 A HUP0000489 A HU P0000489A HU P0000489 A2 HUP0000489 A2 HU P0000489A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- preparation
- pharmaceutical compositions
- same
- Prior art date
Links
- -1 Sulfonamide compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000017911 HTR1A Human genes 0.000 abstract 1
- 101150015707 HTR1A gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Light Receiving Elements (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
A találmány tárgyát az 5-HT1A receptorokkal és/vagy a D2-szerű (D2, D3és D4 alcsoportok) receptorokkal szemben affinitást mutató új (I)általános képletű heteroaril-szulfonamidok - ahol A és B oxigénatomvagy metiléncsoport; g 0, 1, 2, 3 vagy 4; R1 halogénatom vagy adottesetben szubsztituált alkil-, alkoxi-, alkil-tio- vagy metilén-dioxi-csoport; R2 hidrogénatom, alkil- vagy alkoxicsoport; R3 és R4hidrogénatom vagy alkilcsoport; U előnyösen metiléncsoport; Q (IIa),(IIb) vagy (IIc) általános képletű csoport, előnyösen piperidin-1,4-diil-csoport; és T adott esetben szubsztituált aril- vagyheteroarilcsoport - és enantiomereik és sóik, az előállításukraszolgáló eljárás, ezeket tartalmazó gyógyszerkészítmények, valamintgyógyászati alkalmazásuk képezik. A találmány szerinti vegyületekközponti idegrendszeri rendellenességek, cerebrovaszkulárisrendellenességek, neminzulin-függő cukorbetegség és neuroendokrinrendellenességek kezelésére alkalmasak. Ó
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9627006.1A GB9627006D0 (en) | 1996-12-27 | 1996-12-27 | Therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000489A2 true HUP0000489A2 (hu) | 2000-12-28 |
| HUP0000489A3 HUP0000489A3 (en) | 2001-06-28 |
Family
ID=10805084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000489A HUP0000489A3 (en) | 1996-12-27 | 1997-12-15 | Sulfonamide compounds having 5-ht receptor activity, process for their preparation and pharmaceutical compositions containing the same |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6136825A (hu) |
| EP (1) | EP0948498A1 (hu) |
| JP (1) | JP2001508419A (hu) |
| KR (1) | KR20000062356A (hu) |
| CN (1) | CN1247537A (hu) |
| AU (1) | AU747545B2 (hu) |
| BG (1) | BG103557A (hu) |
| BR (1) | BR9714237A (hu) |
| CA (1) | CA2275668A1 (hu) |
| GB (1) | GB9627006D0 (hu) |
| HU (1) | HUP0000489A3 (hu) |
| IL (1) | IL130361A0 (hu) |
| NO (1) | NO993172L (hu) |
| NZ (1) | NZ336328A (hu) |
| PL (1) | PL334254A1 (hu) |
| SK (1) | SK82399A3 (hu) |
| TR (1) | TR199901478T2 (hu) |
| WO (1) | WO1998029411A1 (hu) |
| ZA (1) | ZA9711551B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514663A (ja) | 1997-03-12 | 2001-09-11 | エスモンド，ロバート ダブリュー． | アルツハイマー病を処置または予防するための方法 |
| GB9915617D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
| SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| US6399617B1 (en) | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
| WO2005080394A1 (en) * | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| US20080299674A1 (en) * | 2004-07-14 | 2008-12-04 | Yoshikazu Kitano | Novel Isonitrile Compound, Its Method Of Manufacture, A Marine Fouling Organism Larva Fluorescent, And A Method Of Detecting This Marine Fouling Organism Larva Using Said Marker |
| PT1831159E (pt) * | 2004-12-21 | 2010-03-03 | Hoffmann La Roche | Derivados de tetralina e de indano e as suas utilizações |
| PL395470A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| US5300523A (en) * | 1988-07-28 | 1994-04-05 | Bayer Aktiengesellschaft | Substituted aminomethyltetralins and their heterocyclic analogues |
| FR2681325B1 (fr) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique. |
| FR2701479B1 (fr) * | 1993-02-11 | 1995-05-12 | Pf Medicament | Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique. |
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
-
1996
- 1996-12-27 GB GBGB9627006.1A patent/GB9627006D0/en active Pending
-
1997
- 1997-12-15 US US09/331,066 patent/US6136825A/en not_active Expired - Lifetime
- 1997-12-15 NZ NZ336328A patent/NZ336328A/xx unknown
- 1997-12-15 HU HU0000489A patent/HUP0000489A3/hu unknown
- 1997-12-15 CA CA002275668A patent/CA2275668A1/en not_active Abandoned
- 1997-12-15 JP JP52957498A patent/JP2001508419A/ja active Pending
- 1997-12-15 CN CN97181916A patent/CN1247537A/zh active Pending
- 1997-12-15 EP EP97953819A patent/EP0948498A1/en not_active Withdrawn
- 1997-12-15 BR BR9714237-9A patent/BR9714237A/pt not_active IP Right Cessation
- 1997-12-15 PL PL97334254A patent/PL334254A1/xx unknown
- 1997-12-15 IL IL13036197A patent/IL130361A0/xx unknown
- 1997-12-15 SK SK823-99A patent/SK82399A3/sk unknown
- 1997-12-15 WO PCT/EP1997/007034 patent/WO1998029411A1/en not_active Application Discontinuation
- 1997-12-15 TR TR1999/01478T patent/TR199901478T2/xx unknown
- 1997-12-15 KR KR1019997005840A patent/KR20000062356A/ko not_active Application Discontinuation
- 1997-12-15 AU AU57580/98A patent/AU747545B2/en not_active Ceased
- 1997-12-23 ZA ZA9711551A patent/ZA9711551B/xx unknown
-
1999
- 1999-06-25 NO NO993172A patent/NO993172L/no not_active Application Discontinuation
- 1999-07-06 BG BG103557A patent/BG103557A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB9627006D0 (en) | 1997-02-12 |
| IL130361A0 (en) | 2000-06-01 |
| ZA9711551B (en) | 1999-06-23 |
| US6136825A (en) | 2000-10-24 |
| HUP0000489A3 (en) | 2001-06-28 |
| NZ336328A (en) | 2000-09-29 |
| AU5758098A (en) | 1998-07-31 |
| CN1247537A (zh) | 2000-03-15 |
| WO1998029411A1 (en) | 1998-07-09 |
| PL334254A1 (en) | 2000-02-14 |
| CA2275668A1 (en) | 1998-07-09 |
| NO993172D0 (no) | 1999-06-25 |
| NO993172L (no) | 1999-06-25 |
| JP2001508419A (ja) | 2001-06-26 |
| BR9714237A (pt) | 2000-04-18 |
| BG103557A (en) | 2000-06-30 |
| SK82399A3 (en) | 2000-05-16 |
| TR199901478T2 (xx) | 1999-09-21 |
| EP0948498A1 (en) | 1999-10-13 |
| KR20000062356A (ko) | 2000-10-25 |
| AU747545B2 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902471A2 (hu) | Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| DK0533280T3 (da) | Ny medicinsk anvendelse af tachykininantagonister | |
| HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
| DE69503803D1 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament | |
| IS2503B (is) | Ný efnasambönd | |
| AU2003264915A1 (en) | Piperazine substituted aryl benzodiazepines | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| HUP0203194A2 (hu) | Új fenil-piperazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE69819891D1 (de) | Spiro chinuclidin-derivate, ihre herstellung und verwendung | |
| PE41796A1 (es) | Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. | |
| HUP9900351A2 (hu) | 2-(4-Helyettesített)-benzilamino-2-metil-propánamidszármazékok, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0003413A2 (hu) | Új kondenzált piridinszármazékok, eljárás előállításukra és az azokat tartalmazó gyógyászati készítmények | |
| HUP0301458A2 (hu) | Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása | |
| HUP0000489A2 (hu) | 5-HT-Receptor affinitású szulfonamidszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0500201A2 (hu) | Policiklusos vegyületek, mint potenciális alfa2-adrenoceptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| ES2154605B1 (es) | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 | |
| ATE247104T1 (de) | Azaring-ether-derivate und ihre verwendung als nicotinic-ach-rezeptormodulatoren | |
| HUP0001165A2 (hu) | NK1 és NK2 antagonista hatású acil-amino-alkil-amid-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra | |
| HUP9801950A2 (hu) | 2-(Aril-fenil-amino)-imidazolin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0100926A2 (hu) | Benzilpiperazinil- és benzilpiperidiniletanon-származékok, előállításuk és alkalmazásuk dopamin D4 receptor antagonistaként | |
| HUP0001093A2 (hu) | 5-HT2A-antagonista oxazolidinon-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| FR2613364B1 (fr) | Nouvelles amines tricycliques derivees du tetrahydro-5, 6, 7, 8 naphto (2, 3b) dihydro-2, 3 furanne, et du tetrahydro-6, 7, 8, 9 5h-benzocyclohepta (2, 3b) dihydro-2, 3 furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| FI905957A0 (fi) | Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet. | |
| EP1366044B1 (en) | 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl ]-1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the serotonin reuptake site |